UBS’s Genetic Technologies Ltd. GENE Stock Holding History

UBS’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-100	Closed	-$14K	–	10916
2014 Q1	$14K	Buy	+100	New	+$16K	﹤0.01%	8541
2013 Q4	–	Sell	-6	Closed	-$1K	–	10847
2013 Q3	$1K	Buy	+6	New	+$1.43K	﹤0.01%	10183

Other funds holding GENE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

UBS's GENE Position: Q2 2014 in Review

UBS sold out of Genetic Technologies Ltd. (GENE) in Q2 2014, closing a stake of 100 shares — an estimated $14K sold.

UBS first reported a position in GENE in Q3 2013 and held it in 2 quarters. The position peaked at $14K in Q1 2014. 10 funds tracked by Wall St. Rank hold GENE as of Q2 2014.

UBS reported no remaining Genetic Technologies Ltd. position as of Q2 2014 after selling out during the quarter.
UBS sold 100 Genetic Technologies Ltd. shares in Q2 2014, an estimated $14K.
UBS first reported a position in Genetic Technologies Ltd. in Q3 2013 and held it in 2 quarters.
UBS's Genetic Technologies Ltd. position peaked at $14K in Q1 2014.
10 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.